1.Evening Primrose (Oenothera biennis) Oil in Management of Female Ailments
Journal of Menopausal Medicine 2019;25(2):74-82
Oenothera biennis with the common name of “evening primrose” is containing a valuable fixed oil with commercial name of EPO. Evening primrose oil has two types of omega-6-fatty acid including linoleic acid (60%–80%) and γ-linoleic acid (8%–14%). Essential fatty acids are considered as essential compounds for body health, especially among women. The aim of this study was to evaluate the efficacy of evening primrose oil in the management of women ailments. The document was prepared by investigation in scientific articles of electronic resources (Google Scholar, PubMed, Science Direct, Wiley, Scopus, and Springer) by keywords of evening primrose oil and women. The results of our investigations showed that evening primrose oil has been the subject of several clinical studies, including premenstrual syndrome (PMS), hot flash, mastalgia, fibroadenomas, gestational diabetes, cervical ripening, and dilation. The major clinical studies are focused on mastalgia, followed by PMS. The results of studies confirmed the evening primrose oil's efficacy in women health, but the immediate response should not be expected from it, therefore, it should be regularly used up to 4 or 6 months.
Cervical Ripening
;
Diabetes, Gestational
;
Fatty Acids, Essential
;
Female
;
Fibroadenoma
;
Humans
;
Linoleic Acid
;
Mastodynia
;
Oenothera biennis
;
Pregnancy
;
Premenstrual Syndrome
2.Antioxidant and antiobesity activities of oral treatment with ethanol extract from sprout of evening primrose (Oenothera laciniata) in high fat diet-induced obese mice
Chung Shil KWAK ; Mi Ju KIM ; Sun Gi KIM ; Sunyeong PARK ; In Gyu KIM ; Heun Soo KANG
Journal of Nutrition and Health 2019;52(6):529-539
PURPOSE: Sprouts of evening primrose (Oenothera laciniata, OL) were reported to have high contents of flavonoids and potent antioxidant activity. This study examined the antioxidant and antiobesity activities of OL sprouts to determine if they could be a natural health-beneficial resource preventing obesity and oxidative stress.METHODS: OL sprouts were extracted with 50% ethanol, evaporated, and lyophilized (OLE). The in vitro antioxidant activity of OLE was examined using four different tests. The antiobesity activity and in vivo antioxidant activity from OLE consumption were examined using high fat diet-induced obese (DIO) C57BL/6 mice.RESULTS: The IC₅₀ for the 2,2-diphenyl-1-picryl-hydrazyl (DPPH) radical scavenging and superoxide dismutase (SOD)-like activities of OLE were 26.2 µg/mL and 327.6 µg/mL, respectively. OLE exhibited the ferric reducing antioxidant power (FRAP) activity of 56.7 µg ascorbic acid eq./mL at 100 µg/mL, and an increased glutathione level by 65.1% at 200 µg/mL compared to the control in the hUC-MSC stem cells. In an animal study, oral treatment with 50 mg or 100 mg of OLE/kg body weight for 14 weeks reduced the body weight gain, visceral fat content, fat cell size, blood leptin, and triglyceride levels, as well as the atherogenic index compared to the high fat diet control group (HFC) (p < 0.05). The blood malondialdehyde (MDA) level and the catalase and SOD-1 activities in adipose tissue were reduced significantly by the OLE treatment compared to HFC as well (p < 0.05). In epididymal adipose tissue, the OLE treatment reduced the mRNA expression of leptin, PPAR-γ and FAS significantly (p < 0.05) compared to HFC while it increased adiponectin expression (p < 0.05).CONCLUSION: OLE consumption has potent antioxidant and antiobesity activities via the suppression of oxidative stress and lipogenesis in DIO mice. Therefore, OLE could be a good candidate as a natural resource to develop functional food products that prevent obesity and oxidative stress.
Adipocytes
;
Adipokines
;
Adiponectin
;
Adipose Tissue
;
Animals
;
Ascorbic Acid
;
Body Weight
;
Catalase
;
Diet, High-Fat
;
Ethanol
;
Flavonoids
;
Functional Food
;
Glutathione
;
In Vitro Techniques
;
Intra-Abdominal Fat
;
Leptin
;
Lipogenesis
;
Malondialdehyde
;
Mice
;
Mice, Obese
;
Natural Resources
;
Obesity
;
Oenothera biennis
;
Oxidative Stress
;
RNA, Messenger
;
Stem Cells
;
Superoxide Dismutase
;
Triglycerides
3.Effect of Evening Primrose Oil on Korean Patients With Mild Atopic Dermatitis: A Randomized, Double-Blinded, Placebo-Controlled Clinical Study.
Bo Young CHUNG ; Sook Young PARK ; Min Je JUNG ; Hye One KIM ; Chun Wook PARK
Annals of Dermatology 2018;30(4):409-416
BACKGROUND: Atopic dermatitis (AD) is related to a deficiency of delta-6-desaturase, an enzyme responsible for converting linoleic acid to gamma-linolenic acid (GLA). Evening primrose oil (EPO) as a source of GLA has been of interest in the management of AD. OBJECTIVE: The aim of this randomized, double-blinded, placebo-controlled clinical study is to evaluate the efficacy and safety of EPO in Korean patients with AD. METHODS: Fifty mild AD patients with an Eczema Area Severity Index (EASI) score of 10 or less were enrolled and randomly divided into two groups. The first group received an oval unmarked capsule containing 450 mg of EPO (40 mg of GLA) per capsule, while placebo capsules identical in appearance and containing 450 mg of soybean oil were given to the other group. Treatment continued for a period of four months. EASI scores, transepidermal water loss (TEWL), and skin hydration were evaluated in all the AD patients at the baseline, and in months 1, 2, 3, and 4 of the study. RESULTS: At the end of month 4, the patients of the EPO group showed a significant improvement in the EASI score (p=0.040), whereas the patients of the placebo group did not. There was a significant difference in the EASI score between the EPO and placebo groups (p=0.010). Although not statistically significant, the TEWL and skin hydration also slightly improved in the EPO patients group. CONCLUSION: We suggest that EPO is a safe and effective medicine for Korean patients with mild AD.
Capsules
;
Clinical Study*
;
Dermatitis, Atopic*
;
Eczema
;
gamma-Linolenic Acid
;
Humans
;
Linoleic Acid
;
Linoleoyl-CoA Desaturase
;
Oenothera biennis*
;
Skin
;
Soybean Oil
;
Water
4.A Study on the Statistical Method for the Target Component of a Glucose-lowering Functional Material in Extracts of Evening Primerose Seeds.
Sang Wook PARK ; Joon Seok BANG ; Wonjae LEE
Korean Journal of Clinical Pharmacy 2016;26(1):70-76
BACKGROUND: The use of the extracts from evening primrose seeds as a health functional food has been gradually increased. Therefore, the monitoring and screening process has been considerably required for its quality control. OBJECTIVE: This study aimed to estimate the measurement uncertainty associated with determination of penta-o-galloyl β-D-glucose (PGG) in extracts from evening primrose seeds by high-performance liquid chromatography. METHODS: The sources of measurement uncertainty was expressed in accordance with mathematical/statistical theories of GUM & EURACHEM Guide. The expanded uncertainty was calculated by using the relative standard uncertainty between analytical result and sources of uncertainty in measurement (sample weight, final volume, extraction volume, standard solution, matrix and instrument etc). RESULTS: In the results of 95% confidence interval, the uncertainty in measurement was 10,253.34 ± 1,844.50 µg/kg (k = 2.0). CONCLUSION: In this study, it showed that the value of uncertainty in measurement for determination of PGG in extracts from evening primrose seeds by HPLC has about 18.0% influence on PGG contents of the analytical results. The results would be very useful for the monitoring and screening of evening primrose seeds marketed in Korea for its quality control as dietary supplement.
Chromatography, High Pressure Liquid
;
Chromatography, Liquid
;
Dietary Supplements
;
Functional Food
;
Gingiva
;
Korea
;
Mass Screening
;
Oenothera biennis
;
Prostaglandins G
;
Quality Control
;
Uncertainty
5.Development of a Complete Atrioventricular Block Associated with Intake of Evening Primrose Oil.
In Sun MIN ; Ju Young LEE ; Tae Seob JUNG ; Nam Kyu KANG ; Bo Bae PARK ; Bae Keun KIM
Korean Journal of Medicine 2016;90(5):440-443
A complete atrioventricular block is seen in patients due to a variety of causes, including drugs. The resolution of a drug-induced atrioventricular block is often accomplished by drug discontinuation. We report a case of a complete atrioventricular block in a 31-year-old woman following a month of treatment with evening primrose oils. After excluding all other likely causes of conduction disorders, an adverse effect of the evening primrose oils seemed to be the most likely diagnosis. After discontinuation of the oils, no associated symptoms or conduction disturbances were observed for 4 months after discharge. We stress the reconsideration of taking medicines and functional foods continuously as most patients are not aware of the hazards they pose.
Adult
;
Atrioventricular Block*
;
Diagnosis
;
Female
;
Functional Food
;
Humans
;
Oenothera biennis*
;
Oils
6.Comparative analysis of anti-Helicobacter pylori activities of FEMY-R7 composed of Laminaria japonica and Oenothera biennis extracts in mice and humans.
Tae Su KIM ; Kyungha SHIN ; Joseph H JEON ; Ehn Kyoung CHOI ; Youngjin CHOI ; Sung Pyo LEE ; Yoon Bok LEE ; Yun Bae KIM
Laboratory Animal Research 2015;31(1):7-12
Helicobacter pylori-eliminating effects of FEMY-R7, composed of Laminaria japonica and Oenothera biennis extracts, were investigated in mice and humans. Male C57BL/6 mice were infected with the bacteria by intragastric inoculation (1x10(9) CFU/mouse) 3 times at 2-day intervals, and simultaneously, orally treated twice a day with total 20, 64 or 200 mg/kg/day FEMY-R7 for 2 weeks. In Campylobcter-like organism (CLO)-detection tests on gastric mucosa and feces, FEMY-R7 reduced the urease-positive reactivity in a dose-dependent manner; i.e., the positivity ratios were decreased to 70, 20, and 10% for gastric mocosa and to 80, 50, and 20% for feces. In a clinical sudy, human subjects, confirmed to be infected with Helicobacter pylori, were orally administered twice a day with capsules containing total 100, 320 or 1,000 mg/man/day FEMY-R7 (matching doses for 20, 64 or 200 mg/kg/day, respectively, in mice from a body surface area-based dose translation) for 8 weeks. FEMY-R7 decreased the positivity ratios in feces to 70, 40, and 30%, respectively. In bacterial culture, H. pylori was identified from the CLO-positive stools of mice and humans. The bacterial identification ratios exhibited a good correlation between the matching doses in mice and humans. It is suggested that FEMY-R7 could be a promising functional food without tolerance as an adjunct to reduce the dosage of antibiotics for the treatment of recurrent H. pylori infection.
Animals
;
Anti-Bacterial Agents
;
Bacteria
;
Capsules
;
Feces
;
Functional Food
;
Gastric Mucosa
;
Helicobacter
;
Helicobacter pylori
;
Humans
;
Laminaria*
;
Male
;
Mice*
;
Oenothera biennis*
7.Erratum: In vitro and in vivo anti-Helicobacter pylori activities of FEMY-R7 composed of fucoidan and evening primrose extract.
Jingmei CAI ; Tae Su KIM ; Ja Young JANG ; Jihyun KIM ; Kyungha SHIN ; Sung Pyo LEE ; Ehn Kyoung CHOI ; Sa Hyun KIM ; Min PARK ; Jong Bae KIM ; Yun Bae KIM
Laboratory Animal Research 2015;31(2):99-99
As the request of the authors, Acknowledgments section has been changed.
Oenothera biennis*
8.The Effect of Evening Primrose Oil for the Prevention of Xerotic Cheilitis in Acne Patients Being Treated with Isotretinoin: A Pilot Study.
Kui Young PARK ; Eun Jung KO ; In Su KIM ; Kapsok LI ; Beom Joon KIM ; Seong Jun SEO ; Myeung Nam KIM ; Chang Kwun HONG
Annals of Dermatology 2014;26(6):706-712
BACKGROUND: The most common adverse effects of oral isotretinoin are cheilitis, skin dryness, dry eyes, and conjunctivitis, whereas evening primrose oil (EPO) is known to improve skin moisture and transepidermal water loss (TEWL) in healthy adults and atopic patients. OBJECTIVE: To evaluate the clinical efficacy and safety of EPO in preventing xerotic cheilitis in acne patients being treated with oral isotretinoin. METHODS: Forty Korean volunteers of Fitzpatrick skin types III and IV, having moderate acne, were enrolled and randomized to receive either isotretinoin with or without EPO for 8 weeks. The efficacy of treatment was evaluated on the basis of global acne grading system scores, number of inflammatory and noninflammatory lesions, TEWL, corneometry, physician's global assessment, and patient satisfaction. RESULTS: The results after 8 weeks of treatment showed that the TEWL of the lip increased significantly during isotretinoin treatment, whereas the TEWL of the hand dorsum showed no significant change. The increase of the TEWL of the lip was more definite in the control group than in the experimental group. The number of acne lesions decreased significantly in both groups, and there were no differences between them. CONCLUSION: Our study suggests that the addition of EPO improved xerotic cheilitis in acne patients being treated with oral isotretinoin. However, besides TEWL and corneometry assessments, additional studies are required for a complete understanding of the role of EPO in xerotic cheilitis in acne patients being treated with oral isotretinoin.
Acne Vulgaris*
;
Adult
;
Cheilitis*
;
Conjunctivitis
;
Hand
;
Humans
;
Isotretinoin*
;
Lip
;
Oenothera biennis*
;
Patient Satisfaction
;
Pilot Projects*
;
Skin
;
Volunteers
;
Water Loss, Insensible
9.In vitro and in vivo anti-Helicobacter pylori activities of FEMY-R7 composed of fucoidan and evening primrose extract.
Jingmei CAI ; Tae Su KIM ; Ja Young JANG ; Jihyun KIM ; Kyungha SHIN ; Sung Pyo LEE ; Ehn Kyoung CHOI ; Sa Hyun KIM ; Min PARK ; Jong Bae KIM ; Yun Bae KIM
Laboratory Animal Research 2014;30(1):28-34
Effects of FEMY-R7, composed of fucoidan and evening primrose extract, on the bacterial growth and intragastric infection of Helicobacter pylori as well as gastric secretion were investigated in comparison with a proton-pump inhibitor pantoprazole. For in vitro anti-bacterial activity test, H. pylori (1x10(8) CFU/mL) was incubated with a serially-diluted FEMY-R7 for 3 days. As a result, FEMY-R7 fully inhibited the bacterial growth at 100 microg/mL, which was determined to be a minimal inhibitory concentration. In addition, 6-hour incubation with H. pylori, FEMY-R7 inhibited urease activity in a concentration-dependent manner, showing a median inhibitory concentration of 1,500 microg/mL. In vivo elimination study, male C57BL/6 mice were infected with the bacteria by intragastric inoculation (5x10(9) CFU/mouse) 3 times at 2-day intervals, and simultaneously, orally treated twice a day with 10, 30 or 100 mg/kg FEMY-R7 for 7 days. In Campylobcter-like organism-detection test and bacterial identification, FEMY-R7 exerted a high bacteria-eliminating capacity at 30-100 mg/kg, comparably to 30 mg/kg pantoprazole. In contrast to a strong antacid activity of pantoprazole in a pylorus-ligation study, FEMY-R7 did not significantly affect gastric pH, free HCl, and total acidity, although it significantly decreased fluid volume at a low dose (10 mg/kg). The results indicate that FEMY-R7 eliminate H. pylori from gastric mucosa by directly killing the bacteria and preventing their adhesion and invasion, rather than by inhibiting gastric secretion or mucosal damage.
Animals
;
Bacteria
;
Gastric Mucosa
;
Helicobacter pylori
;
Homicide
;
Humans
;
Hydrogen-Ion Concentration
;
Male
;
Mice
;
Oenothera biennis*
;
Urease
10.Anti-Helicobacter pylori activities of FEMY-R7 composed of fucoidan and evening primrose extract in mice and humans.
Tae Su KIM ; Ehn Kyoung CHOI ; Jihyun KIM ; Kyungha SHIN ; Sung Pyo LEE ; Youngjin CHOI ; Joseph H JEON ; Yun Bae KIM
Laboratory Animal Research 2014;30(3):131-135
Helicobacter pylori-eliminating effects of FEMY-R7, composed of fucoidan and evening primrose extract, were investigated in mice and humans. Male C57BL/6 mice were infected with the bacteria by intragastric inoculation (1x10(9) CFU/mouse) 3 times at 2-day intervals, and simultaneously, orally treated twice a day with 10 or 100 mg/kg FEMY-R7 for 2 weeks. In Campylobcter-like organism-detection test, FEMY-R7 markedly reduced the urease-positive reactivity. In a clinical sudy, human subjects, confirmed to be infected with Helicobacter pylori, were orally administered twice a day with a capsule containing 150 mg FEMY-R7 for 8 weeks. FEMY-R7 significantly decreased both the Delta over baseline-value in urea breath test and the serum pepsinogens I and II levels. The results indicate that FEMY-R7 not only eliminates H. pylori from gastric mucosa of animals and humans, but also improves gastric function.
Animals
;
Bacteria
;
Breath Tests
;
Gastric Mucosa
;
Helicobacter
;
Helicobacter pylori
;
Humans
;
Male
;
Mice*
;
Oenothera biennis*
;
Pepsinogen A
;
Pepsinogens
;
Urea

Result Analysis
Print
Save
E-mail